A pharmaceutical composition for preventing or treating a disease or disorder characterized by chronic inflammation associated with angiogenesis and fibrosis. The pharmaceutical composition includes multi-target inhibitors, multi-phase modulators, or multi-kinase inhibitors, such as axitinib, nidanib, pirfenidone, leoxifene, sorafenib, sunitinib Nirvana, Levatinib, Rigefenib, Panatinib or Pazopanib.一種用於預防或治療以與血管生成和纖維化相關的慢性炎症為特徵的疾病或疾患的藥物組合物。所述藥物組合物包括多靶抑制劑、多相調節劑或多激酶抑制劑，諸如阿西替尼、尼達尼布、吡非尼酮、利奧西呱、索拉非尼、舒尼替尼、樂伐替尼、瑞格非尼、帕納替尼或帕唑帕尼。
